Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 1 Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1 Advanced Head and Neck Carcinoma 1

Interventions

Everolimus 7 Nivolumab 6 Cisplatin 6 Temozolomide 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Fluorouracil 4 Carboplatin 4 pembrolizumab 3 avelumab 3 atezolizumab 3 Irinotecan 3 Ipilimumab 3 Etoposide 3 Capecitabine 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 Radiosurgery 2 Positron Emission Tomography Computed Tomography 2 Paclitaxel 2 PE regimen 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 Drug Therapy 2 Disulfides 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Neuroendocrine × Radiopharmaceuticals × Clear all

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡